Sensitive skin is common but until now there has been no scale for measuring its severity. The Sensitive Scale is a new scale with a 14-item and a 10-item version that was tested in 11 countries in different languages on 2,966 participants. The aim of this study was to validate the pertinence of using the Sensitive Scale to measure the severity of sensitive skin. The internal consistency was high. Correlations with the dry skin type, higher age, female gender, fair phototypes and Dermatology Life Quality Index were found. Using the 10-item version appeared to be preferable because it was quicker and easier to complete, with the same internal consistency and the 4 items that were excluded were very rarely observed in patients. The mean initial scores were around 44/140 and 37/100. The use of a cream for sensitive skin showed the pertinence of the scale before and after treatment.
Sensitive skin in Brazil and Russia: An epidemiological and comparative approachBackground: Sensitive skin is characterized by the occurrence of sensations of tingling, prickling, heat, burning, pain or itching and, on occasion, erythema, in response to multiple physical, chemical or hormonal factors that do not have irritant properties by themselves. Objective: We chose here to evaluate sensitive skin in two countries with very different populations, climates and lifestyles: Russia and Brazil. Method: Representative nationwide samples of the Russian and Brazilian populations aged 15 and over were selected. The same methodology was used: the individuals were questioned by telephone and selected as per the quotas method (sex, age, householder profession, rural/urban location and region). Results: In the Brazilian population, 22.3% versus 45.7%, in favour of women, reported having a "sensitive" skin. Significant differences were only observed by geographic residence. In the Russian population, 25.4% versus 50.1%, in favour of women, reported having a "sensitive" skin. Significant differences were observed in skin sensitivity according to social-professional categories, region of residence and subject age. The same results were found in both populations for sensitivity to cosmetics and food intake. Conclusion: Respondents with rather sensitive or very sensitive skin are 2 or 3 times more reactive to climatic, environmental factors, cosmetics and food intake.
Atopic dermatitis (AD) occurs in approximately 2-3% of adults. The aim of this study was to develop and validate the self-administered Atopic Dermatitis Burden Scale for Adults (ABS-A). Patients were enrolled consecutively from those attending the Station Thermale Avène for a diagnosis of AD. ABS-A was developed using standard methodology, and consisted of 3 phases: exploratory, development, and validation. Internal consistency (Cronbach's α), concurrent validity (Spearman's correlation between ABS-A, SF-12 and Dermatology Life Quality Index [DLQI)]), and discriminant validity, were analysed. A total of 128 adults (68.8% females) completed the ABS-A, consisting of 18 items grouped into 4 domains. ABS-A showed good internal coherence (Cronbach's α, 0.89) and was correlated with both SF-12 components [r = -0.36, p < 0.0001 (Physical); r = -0.52, p < 0.0001 (Mental)] and DLQI (r = 0.78; p < 0.0001). The ABS-A score varied significantly according to AD severity. To our knowledge, ABS-A is the first specific tool for assessing AD burden in adult patients.
Using a new simple dermatoporosis self-diagnosis tool, this study provides a previously unprecedented insight into the high prevalence of dermatoporosis in elderly individuals. IDA questionnaire is a short (14-item) and easy to use tool for evaluating dermatoporosis in adults and may allow an easy evaluation of each subject.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.